全文获取类型
收费全文 | 1692篇 |
免费 | 79篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 19篇 |
妇产科学 | 26篇 |
基础医学 | 226篇 |
口腔科学 | 103篇 |
临床医学 | 137篇 |
内科学 | 484篇 |
皮肤病学 | 18篇 |
神经病学 | 164篇 |
特种医学 | 57篇 |
外科学 | 179篇 |
综合类 | 11篇 |
预防医学 | 64篇 |
眼科学 | 27篇 |
药学 | 161篇 |
中国医学 | 31篇 |
肿瘤学 | 53篇 |
出版年
2023年 | 5篇 |
2022年 | 24篇 |
2021年 | 47篇 |
2020年 | 28篇 |
2019年 | 41篇 |
2018年 | 40篇 |
2017年 | 45篇 |
2016年 | 45篇 |
2015年 | 58篇 |
2014年 | 77篇 |
2013年 | 69篇 |
2012年 | 111篇 |
2011年 | 115篇 |
2010年 | 59篇 |
2009年 | 65篇 |
2008年 | 96篇 |
2007年 | 96篇 |
2006年 | 81篇 |
2005年 | 73篇 |
2004年 | 80篇 |
2003年 | 64篇 |
2002年 | 64篇 |
2001年 | 34篇 |
2000年 | 29篇 |
1999年 | 22篇 |
1998年 | 13篇 |
1997年 | 8篇 |
1996年 | 8篇 |
1995年 | 18篇 |
1994年 | 14篇 |
1993年 | 14篇 |
1992年 | 21篇 |
1991年 | 29篇 |
1990年 | 18篇 |
1989年 | 23篇 |
1988年 | 15篇 |
1987年 | 22篇 |
1986年 | 16篇 |
1985年 | 13篇 |
1984年 | 14篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1974年 | 5篇 |
1971年 | 3篇 |
1970年 | 5篇 |
1966年 | 3篇 |
排序方式: 共有1779条查询结果,搜索用时 15 毫秒
21.
Goren N Manzano A Riera L Ambrosio S Ventura F Bartrons R 《Brain research. Molecular brain research》2000,75(1):138-142
This study reports the expression of the ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3) (PFK-2/FBPase-2) in different stages of rat brain development. Northern blot and RT-PCR analysis demonstrated that ubiquitous PFK-2/FBPase-2 is expressed in rat brain from embryonic to adult life and shows a transient increase 1 day before birth, coincident with the maximum concentration of Fru-2,6-P(2) and PFK-2 activity. The levels of brain PFK-2/FBPase-2 gene expression as well as the enzymatic activity and the concentration of Fru-2,6-P(2) appear to be remarkably constant during adult life, without significant differences in the brain hippocampus, cortex, cerebellum or striatum areas. 相似文献
22.
23.
Yan Wang Phillip R. Musich Moises A. Serrano Yue Zou Jia Zhang Meng-Yang Zhu 《Neurotoxicity research》2014,25(2):193-207
Dopamine β-hydroxylase (DBH) and norepinephrine (NE) transporter (NET) are the noradrenergic phenotypes for their functional importance to noradrenergic neurons. It is known that in vivo N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) treatment induces degeneration of noradrenergic terminals by interacting with NET and depleting intracellular NE. However, DSP4’s precise mechanism of action remains unclear. In this study various biochemical approaches were employed to test the hypothesis that DSP4 down-regulates the expression of DBH and NET, and to determine molecular mechanisms that may be involved. The results showed that treatment of SH-SY5Y neuroblastoma cells with DSP4 significantly decreased mRNA and protein levels of DBH and NET. DSP4-induced reduction of DBH mRNA and proteins, as well as NET proteins showed a time- and concentration-dependent manner. Flow cytometric analysis demonstrated that DSP4-treated cells were arrested predominantly in the S-phase, which was reversible. The arrest was confirmed by several DNA damage response markers (phosphorylation of H2AX and p53), suggesting that DSP4 causes replication stress which triggers cell cycle arrest via the S-phase checkpoints. Moreover, the comet assay verified that DSP4 induced single-strand DNA breaks. In summary, the present study demonstrated that DSP4 down-regulates the noradrenergic phenotypes, which may be mediated by its actions on DNA replication, leading to replication stress and cell cycle arrest. These action mechanisms of DSP4 may account for its degenerative consequence after systematic administration for animal models. 相似文献
24.
25.
Tatiana L. Fonseca Joao Pedro Werneck-De-Castro Melany Castillo Barbara M.L.C. Bocco Gustavo W. Fernandes Elizabeth A. McAninch Daniele L. Ignacio Caio C.S. Moises Alexandre Ferreira Balázs Gereben Antonio C. Bianco 《Diabetes》2014,63(5):1594-1604
Type 2 deiodinase (D2) converts the prohormone thyroxine (T4) to the metabolically active molecule 3,5,3′-triiodothyronine (T3), but its global inactivation unexpectedly lowers the respiratory exchange rate (respiratory quotient [RQ]) and decreases food intake. Here we used FloxD2 mice to generate systemically euthyroid fat-specific (FAT), astrocyte-specific (ASTRO), or skeletal-muscle-specific (SKM) D2 knockout (D2KO) mice that were monitored continuously. The ASTRO-D2KO mice also exhibited lower diurnal RQ and greater contribution of fatty acid oxidation to energy expenditure, but no differences in food intake were observed. In contrast, the FAT-D2KO mouse exhibited sustained (24 h) increase in RQ values, increased food intake, tolerance to glucose, and sensitivity to insulin, all supporting greater contribution of carbohydrate oxidation to energy expenditure. Furthermore, FAT-D2KO animals that were kept on a high-fat diet for 8 weeks gained more body weight and fat, indicating impaired brown adipose tissue (BAT) thermogenesis and/or inability to oxidize the fat excess. Acclimatization of FAT-D2KO mice at thermoneutrality dissipated both features of this phenotype. Muscle D2 does not seem to play a significant metabolic role given that SKM-D2KO animals exhibited no phenotype. The present findings are unique in that they were obtained in systemically euthyroid animals, revealing that brain D2 plays a dominant albeit indirect role in fatty acid oxidation via its sympathetic control of BAT activity. D2-generated T3 in BAT accelerates fatty acid oxidation and protects against diet-induced obesity. 相似文献
26.
M. Domingos F. Intranuovo A. Gloria R. Gristina L. Ambrosio P.J. Bártolo P. Favia 《Acta biomaterialia》2013,9(4):5997-6005
Cellular adhesion and proliferation inside three-dimensional synthetic scaffolds represent a major challenge in tissue engineering. Besides the surface chemistry of the polymers, it is well recognized that scaffold internal architecture, namely pore size/shape and interconnectivity, has a strong effect on the biological response of cells. This study reports for the first time how polycaprolactone (PCL) scaffolds with controlled micro-architecture can be effectively produced via bioextrusion and used to enhance the penetration of plasma deposited species. Low-pressure nitrogen-based coatings were employed to augment cell adhesion and proliferation without altering the mechanical properties of the structures. X-ray photoelectron spectroscopy carried out on different sections of the scaffolds indicates a uniform distribution of nitrogen-containing groups throughout the entire porous structure. In vitro biological assays confirm that plasma deposition sensitively promotes the activity of Saos-2 osteoblast cells, leading to a homogeneous colonization of the PCL scaffolds. 相似文献
27.
Maria Raffaella Ambrosio Bruno Jim Rocca Maria Grazia Mastrogiulio Alia Lutfi Stefano Lazzi Sergio Antonio Tripodi 《Esophagus》2014,11(2):136-139
Acute esophageal necrosis, commonly referred to as ‘black esophagus?, is a rare clinical entity arising from a combination of ischemic insult, corrosive injury and decreased function of mucosal barrier systems and reparative mechanisms present in debilitating diseases. We describe the case of an 18-year-old man affected by Down syndrome, presenting with a streptococcus β-hemolytic group A infection of the upper airways. Although the patient was intensively treated with antibiotics, he developed a streptococcal toxic shock-like syndrome and died 5 days after admission. At autopsy, circumferential black discoloration of the esophageal mucosa that extended along the entire esophagus and ended abruptly at the esophageal-gastric junction was found. Neither ulceration nor esophageal perforation were present. Black esophagus is well known to the gastroenterology community, whereas it has been described only twice in the pathology literature. To the best of our knowledge, this is the first case ever reported complicating a streptococcal infection. 相似文献
28.
Susanne Halken Desiree Larenas‐Linnemann Graham Roberts Moises A. Calderón Elisabeth Angier Oliver Pfaar Dermot Ryan Ioana Agache Ignacio J. Ansotegui Stefania Arasi George Du Toit Montserrat Fernandez‐Rivas Roy Geerth van Wijk Marek Jutel Jörg Kleine‐Tebbe Susanne Lau Paolo M. Matricardi Giovanni B. Pajno Nikolaos G. Papadopoulos Martin Penagos Alexandra F. Santos Gunter J. Sturm Frans Timmermans R. van Ree Eva‐Maria Varga Ulrich Wahn Maria Kristiansen Sangeeta Dhami Aziz Sheikh Antonella Muraro 《Pediatric allergy and immunology》2017,28(8):728-745
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease‐modifying treatment for IgE‐mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence‐based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer‐review of draft recommendations. Our key recommendation is that a 3‐year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate‐to‐severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post‐AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post‐AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease‐modifying treatment exists but there is an urgent need for more high‐quality clinical trials. 相似文献
29.
30.
M Chiariello G Ambrosio M Cappelli-Bigazzi P Perrone-Filardi I Tritto E Nevola P Golino 《American heart journal》1990,120(4):801-807
It has been suggested that activation of tissue phospholipases may contribute to the development of ischemic cell injury. In the present study we sought to assess whether administration of the phospholipase inhibitor quinacrine would reduce the extent of myocardial necrosis after coronary artery occlusion. In open-chest, anesthetized dogs the left anterior descending coronary artery was ligated, and technetium-99-labeled albumin microspheres were injected into the left atrium to measure the area at risk. The animals were then randomly divided into a control group (n = 8) and a group receiving quinacrine (5 mg/kg intravenous bolus followed by a 40 micrograms/kg/min infusion for 6 hours; n = 9). The animals were killed 6 hours after occlusion, and the infarcted area was delineated by triphenyltetrazolium chloride staining. The extent of the risk region was similar in the two groups (32.3 +/- 2.1% of the left ventricle in control dogs and 34.2 +/- 3.4% in quinacrine-treated dogs). Infarct size was 86.4 +/- 8.8% of the risk region in control animals, whereas in treated dogs it averaged 62.3 +/- 6.4% of the risk region (p = 0.05). No differences were found in heart rate, arterial pressure, and rate-pressure product between the two groups. Thus administration of the phospholipase inhibitor quinacrine reduced the extent of myocardial necrosis in a model of fixed coronary artery occlusion. Preservation of membrane phospholipids, reduced formation of lipoxygenase metabolites, or both may mediate this phenomenon. 相似文献